Molecular Tumor Panels
Better Knowledge - Better Treatment
WHAT is Tumor Testing?
Alterations in genetic makeup can result in the development of cancer. With Next-Generation Sequencing (NGS), we are able to identify these changes. Understanding these mutations can lead to a personalized patient treatment that is tailored to each cancer, sometimes opening up treatment routes that are only available to cancers that developed from these alterations. Thus, mutation profiles of a tumor's DNA can help prioritize therapy and help direct better patient outcomes.
The Lung Cancer Tumor Test is a comprehensive panel consisting of two subdivided panels. Non-Small Cell Lung Cancer (NSCLC) consists of 22 genes; Small Cell Lung Cancer (SCLC) consists of 6 genes.
The Renal Cancer Tumor Test is a comprehensive panel subdivided into two groups. The Adult Renal Carcinoma is a panel consisting of 11 genes.; The Pediatric Wilms Tumor panel consists of 6 genes.